Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyGlobeNewsWire • 01/04/24
Applied Therapeutics: Multiple Inflection Points Could Generate Substantial ValueSeeking Alpha • 01/04/24
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7GlobeNewsWire • 11/01/23
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingGlobeNewsWire • 09/28/23
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023GlobeNewsWire • 09/06/23
Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)Seeking Alpha • 08/17/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDAQ: APLT)PRNewsWire • 06/28/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 06/27/23
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes AssociationGlobeNewsWire • 06/22/23
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD DeficiencyGlobeNewsWire • 05/25/23
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA SubmissionGlobeNewsWire • 04/24/23
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial ResultsGlobeNewsWire • 03/23/23
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 03/01/23
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) DeficiencyGlobeNewsWire • 02/16/23
Applied Therapeutics to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/09/23
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in EuropeGlobeNewsWire • 01/04/23
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022GlobeNewsWire • 10/31/22